Meta-analysis of the Effects of Probiotics on Alcoholic Liver Disease.

Nutr RevSep 6, 2026
Clinical ResearchGastroenterology

Jiadila Bahetiyaer, Arafat Md Ferdous, Qing Hong et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the impact of probiotics on liver function markers in patients with alcoholic liver disease (ALD), analyzing 15 randomized controlled trials. Probiotic therapy significantly reduced alanine aminotransferase (ALT) levels (SMD, -0.50; P = .007) and aspartate aminotransferase (AST) levels (SMD, -0.26; P = .05), indicating potential benefits in managing liver function in this population.

Key findings

  • Probiotics significantly reduced ALT levels (SMD, -0.50; P = .007).
  • AST levels also decreased significantly with probiotics (SMD, -0.26; P = .05).
  • No significant effects were observed on total bilirubin, albumin, or gamma-glutamyl transferase levels.
  • Asian patients showed a significant reduction in ALT levels with probiotic treatment.

Why it matters

The findings suggest that probiotics may be a beneficial adjunctive treatment for improving liver function in patients with alcoholic liver disease, particularly in reducing ALT levels, which is crucial for monitoring liver health.

Source

PubMed · PMID 41328641

Published in Nutr Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.